IP Library Granted Patent US 9,920,016
Granted Patent B2
US 9,920,016 · App. 15/379,553 · Granted Mar 20, 2018

Process for the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one

Inventors: Deog Joong Kim (Rockville, MD); Haifeng Yin (Shanghai, CN); Eliezer Falb (Givatayim, IL); Leigh Andre Pearcey (Didcot, GB); Jonathan Cummins (Didcot, GB); Petra Dieterich (Abingdon, GB); Jean-Francois Carniaux (Abingdon, GB); Yi Wang (Chester Springs, PA); Vikram Chandrakant Purohit (Downingtown, PA)
Assignee: REXAHN PHARMACEUTICALS, INC.
C07D239/47C07D317/22C07D317/44C07D405/04C07F7/1892
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,920,016
App. No.
15/379,553
Granted
Mar 20, 2018
Kind
B2
Abstract

Processes for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3 -hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one(13, RX-3117) and its intermediates are described.

Claims (34)

1. A process for the preparation of (1R,4S,5S)-2-iodo-4,5-isopropylidenedioxy-1-(trityloxymethyl)cyclopent-2-enol (5) from (3aR,6aR)-2,2-dimethyl-6-((trityloxy)methyl)tetrahydrofuro[3,4-d][1,3]dioxol-4-ol (2), comprising:

reacting (3aR,6aR)-2,2-dimethyl-6-((trityloxy)methyl)tetrahydrofuro[3,4-d][1,3]dioxol-4-ol (2) with iodoform to form 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3).

2. The process of claim 1 , further comprising:

oxidizing 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3) to form 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4).

3. The process of claim 2 , wherein the step of oxidizing 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3 -dioxolan-4-yl)-2-(trityloxy)ethanol (3) to form 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4) comprises Swern oxidation with diisopropylcarbodiimide, pyridine, trifluoroacetic acid (CF3COOH), and sodium hypochlorite (NaOCl ).

4. The process of claim 2 , further comprising:

reacting 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4) with n-BuLi to form (1R,4S,5S)-2-iodo-4,5-isopropylidenedioxy-1-(trityloxymethyl)cyclopent-2-enol (5).

5. The process of claim 1 , further comprising:

oxidizing 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3) to form 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4); and

reacting 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4) with n-BuLi to form (1R,4S,5S)-2-Iodo-4,5-isopropylidenedioxy-1-(trityloxymethyl)cyclopent-2-enol (5).

6. A process for the preparation of 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3), comprising:

reacting (3aR,6aR)-2,2-dimethyl-6-((trityloxy)methyl)tetrahydrofuro[3,4-d][1,3]dioxol-4-ol (2) with iodoform to form 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3).

7. A process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy -3-(hydroxymethyl)-cyclopent-2-en-1-yl)-pyrimidin-2(1H)-one (13), comprising:

reacting (3aR,6aR)-2,2-dimethyl-6-((trityloxy)methyl)tetrahydrofuro[3,4-d][1,3]dioxol-4-ol (2) with iodoform to form 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3); and

isolating 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)-cyclopent-2-en-1-yl)-pyrimidin-2(1H)-one(13).

8. The process of claim 7 , further comprising:

oxidizing 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3) to form 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4).

9. The process of claim 8 , wherein the step of oxidizing 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3) to form 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4) comprises Swern oxidation with diisopropylcarbodiimide, pyridine, trifluoroacetic acid (CF3COOH), and sodium hypochlorite (NaOCl).

10. The process of claim 8 , further comprising:

reacting 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4) with n-BuLi to form (1R,4S,5S)-2-iodo-4,5-isopropylidenedioxy-1-(trityloxymethyl)cyclopent-2-enol (5).

11. The process of claim 10 , further comprising:

oxidizing (1R,4S,5S)-2-iodo-4,5-isopropylidenedioxy-1-(trityloxymethyl)cyclopent-2-enol (5) to form (3aR,6aR)-5-iodo-2,2-dimethyl-6-((trityloxy)methyl)-3aH-cyclopenta[d][1,3]dioxol-4(6aH)-one(6).

12. The process of claim 7 , further comprising:

oxidizing 1-((4R,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanol (3) to form 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4); and

reacting 1-((4S,5S)-5-(2,2-diiodovinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone (4) with n-BuLi to form (1R,4S,5S)-2-Iodo-4,5-isopropylidenedioxy-1-(trityloxymethyl)cyclopent-2-enol (5).

13. The process of claim 7 , further comprising:

reacting 4-amino-1-(3aS,4S,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl) pyrimidin-2(1H)-one(12) with an acid to form 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)-cyclopent-2-en-1-yl)-pyrimidin-2(1H)-one (13).

14. The process of claim 13 , further comprising:

reacting (3aR,4R,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl methanesulfonate(11) with cytosine to form 4-amino-1-(3aS,4S,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl) pyrimidin-2(1H)-one(12).

15. The process of claim 14 , further comprising:

reacting (3aS,4R,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol(10) with MsCl to form (3aR,4R,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl methanesulfonate (11).

16. The process of claim 13 , further comprising:

reacting (3aS,4R,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol(10) with MsCl to form (3aR,4R,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl methanesulfonate(11); and

reacting (3aR,4R,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl methanesulfonate (11) with cytosine to form 4-amino-1-(3aS,4S,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH -cyclopenta[d][1,3]dioxol -4-yl)pyrimidin-2(1H)-one(12).

Assignments (7)
CHANGE OF NAME Recorded Nov 4, 2021
From: REXAHN PHARMACEUTICALS, INC.
To: OCUPHIRE PHARMA, INC.
Reel/Frame 058032/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2017
From: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
To: REXAHN PHARMACEUTICALS, INC.
Reel/Frame 043490/0118 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2017
From: YIN, HAIFENG; KIM, DEOG JOONG; PEARCEY, LEIGH ANDRE; CUMMINS, JONATHAN; DIETERICH, PETRA; CARNIAUX, JEAN-FRANCOIS
To: REXAHN PHARMACEUTICALS, INC.
Reel/Frame 043331/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2017
From: WANG, YI; PUROHIT, VIKRAM CHANDRAKANT
To: TEVA PHARMACEUTICAL INDUSTRIES, LTD.; REXAHN PHARMACEUTICALS, INC.
Reel/Frame 043331/0796 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2017
From: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
To: REXAHN PHARMACEUTICALS, INC.
Reel/Frame 043331/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2017
From: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
To: REXAHN PHARMACEUTICALS, INC.
Reel/Frame 043331/0776 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2017
From: FALB, ELIEZER
To: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Reel/Frame 043331/0742 →
Continuity (4)
Continuation 14845968 · Sep 4, 2015
Continuation 14216242 · Mar 17, 2014
Provisional Application 61800475 · Mar 15, 2013
Related Publication 20170158662A1 · Jun 8, 2017